Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 28, 2025 16:30 ET | Source: Akebia Therapeutics, Inc.

Akebia Therapeutics Provides Update on Vafseo for Non-Dialysis Patients

CAMBRIDGE, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
October 20, 2025 08:08 ET | Source: Akebia Therapeutics, Inc.

Akebia Therapeutics Announces Five Presentations at ASN Kidney Week 2025

CAMBRIDGE, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
October 01, 2025 16:05 ET | Source: Akebia Therapeutics, Inc.

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
September 02, 2025 16:05 ET | Source: Akebia Therapeutics, Inc.

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
August 28, 2025 08:00 ET | Source: Akebia Therapeutics, Inc.

Akebia Therapeutics to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
August 21, 2025 08:00 ET | Source: Akebia Therapeutics, Inc.

Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo® (vadadustat) Across All IRC Dialysis Clinics

CAMBRIDGE, Mass. and FRANKLIN, Tenn., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted...
August 07, 2025 07:00 ET | Source: Akebia Therapeutics, Inc.

Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Continued Vafseo® (vadadustat) growth with Q2 2025 net product revenues increasing to $13.3 million; Total Q2 2025 net product revenues increased to $60.5 million DaVita physicians are expected to...
August 06, 2025 08:00 ET | Source: Akebia Therapeutics, Inc.

Akebia Therapeutics to Present at Canaccord Genuity’s 45th Annual Growth Conference

CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
August 04, 2025 08:00 ET | Source: Akebia Therapeutics, Inc.

Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization

CAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
August 01, 2025 16:05 ET | Source: Akebia Therapeutics, Inc.

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...